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Abstract
Rationale: Pulmonary arterial hypertension (PAH) is an obstructive
vasculopathy characterized by excessive pulmonary artery smooth
muscle cell (PASMC)proliferation,migration, andapoptosis resistance.
This cancer-like phenotype is promoted by increased cytosolic calcium
([Ca21]cyto), aerobic glycolysis, and mitochondrial ﬁssion.
Objectives: To determine how changes in mitochondrial calcium
uniporter (MCU)complex (MCUC) function inﬂuencemitochondrial
dynamics and contribute to PAH’s cancer-like phenotype.
Methods:PASMCswere isolated frompatientswithPAHandhealthy
control subjects and assessed for expression of MCUC subunits.
Manipulation of the pore-forming subunit, MCU, in PASMCs was
achieved through small interferingRNAknockdownorMCUplasmid-
mediatedup-regulation, aswell as throughmodulationof the upstream
microRNAs (miRs)miR-138 andmiR-25. In vivo, nebulized anti-miRs
were administered to rats with monocrotaline-induced PAH.
Measurements and Main Results: Impaired MCUC function,
resulting from down-regulation of MCU and up-regulation of an
inhibitory subunit, mitochondrial calcium uptake protein 1, is
central to PAH’s pathogenesis. MCUC dysfunction decreases
intramitochondrial calcium ([Ca21]mito), inhibiting pyruvate
dehydrogenase activity and glucose oxidation, while increasing
[Ca21]cyto, promoting proliferation, migration, and ﬁssion. In
PAH PASMCs, increasing MCU decreases cell migration,
proliferation, and apoptosis resistance by lowering [Ca21]cyto,
raising [Ca21]mito, and inhibiting ﬁssion. In normal PASMCs,
MCUC inhibition recapitulates the PAH phenotype. In PAH,
elevatedmiRs (notablymiR-138) down-regulateMCUdirectly and
also by decreasing MCU’s transcriptional regulator cAMP
response element–binding protein 1. Nebulized anti-miRs against
miR-25 and miR-138 restore MCU expression, reduce cell
proliferation, and regress established PAH in the monocrotaline
model.
Conclusions: These results highlight miR-mediated MCUC
dysfunction as a unifying mechanism in PAH that can be
therapeutically targeted.
Keywords: mitochondrial calcium uptake protein 1; microRNA-
25- and -138-5p; cAMP response element–binding protein;
pyruvate dehydrogenase
Pulmonary arterial hypertension (PAH) is
an obstructive, arterial vasculopathy in
which disorders of endothelial cells,
pulmonary artery smooth muscle cells
(PASMCs), ﬁbroblasts, and inﬂammatory
cells cause loss of vascular lumen, vascular
stiffening, and vasoconstriction (1). This
adverse vascular remodeling increases
right ventricular (RV) afterload,
ultimately causing death from RV failure.
Although vasoconstriction is a major
pathophysiologic feature in only
approximately 5% of patients (2), the
approved PAH-targeted therapeutics are
primarily vasodilators. Consequently,
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prognosis remains poor with survival rates
of approximately 50% at 5 years (2). This
suggests the need to better understand and
therapeutically target nonvasospastic
pathways, such as PAH’s cancer-like
phenotype, which is exempliﬁed by
excessive proliferation and apoptosis
resistance. Underlying this phenotype are
cancer-like changes in mitochondrial
metabolism (1, 3) and dynamics (4, 5),
as well as an increase in intracellular
calcium and plasmalemmal membrane
depolarization that is secondary to the
down-regulation of voltage-gated
potassium channels (6).
In PAH PASMCs (7, 8) and
endothelial cells (9) glycolysis is
uncoupled from glucose oxidation. This
metabolic shift, ﬁrst observed in cancer
cells by Warburg (10), results in part
from pyruvate dehydrogenase (PDH)
kinases–mediated inhibition of PDH (3),
which suppresses apoptosis while
increasing proliferation (1, 3). Recently
another mitochondrial abnormality has
been discovered in PAH PASMCs, namely
fragmentation of the mitochondrial
network. This is due to increased ﬁssion,
caused by post-translational activation of
dynamin-related protein 1 (Drp1) (4),
and impaired fusion, caused by down-
regulation of mitofusin-2 (11).
Vasoconstriction and cell proliferation
in PAH are also driven by elevation of
cytosolic calcium ([Ca21]cyto) (12),
resulting from increased calcium inﬂux
through the L-type calcium channel (caused
by impaired expression of potassium
channels, including Kv1.5 [12, 13]),
activation of TrpC6 (14) channels, and
calcium sensitization (6). Regulation of
intracellular calcium and mitochondrial
bioenergetics are closely linked. Increases
in intramitochondrial Ca21 ([Ca21]mito)
accelerate oxidative metabolism by
activating mitochondrial dehydrogenases,
either directly (oxoglutarate dehydrogenase
and isocitrate dehydrogenase) or indirectly
(by activating PDH phosphatase, which
activates PDH [15–17]). Although it has
long been known that mitochondrial
calcium stores communicate with
cytosolic and sarcoplasmic reticular
calcium pools, it is unknown how
dysregulation of [Ca21]cyto and
[Ca21]mito are linked to mitochondrial
metabolism and dynamics.
Indeed, the molecular mediators of
inﬂow (18, 19) and egress (20, 21) of
mitochondrial calcium have only
recently been identiﬁed. Calcium enters
the mitochondria via the mitochondrial
calcium uniporter (MCU) complex
(MCUC), an inwardly rectifying, Ca21-
selective, ion channel in the inner
mitochondrial membrane (22). The
MCUC’s high Ca21 selectivity at low
[Ca21]cyto (22) allows mitochondrial
uptake and release of calcium to
dynamically buffer [Ca21]cyto (23). The
MCUC has ﬁve components, including
the mitochondrial calcium uptake
protein 1 (MICU1), an inhibitory calcium-
binding protein in the mitochondrial
intermembrane space (24), and the pore-
forming MCU subunit, a 40-kD protein
in the inner mitochondrial membrane
(18, 25, 26). Although loss of MCU is not
lethal to cells (or mice), it reduces
mitochondrial matrix calcium (18) and
lowers PDH activity in skeletal muscle
(15). In contrast, MCU overexpression
increases mitochondrial matrix calcium
(18), which sensitizes cells to apoptotic
stimuli (27).
We report that decreased MCUC
function, caused by decreased expression of
MCU and increased expression of MICU1,
underlies key phenotypic features of
PAH including elevation of [Ca21]cyto,
reduction of [Ca21]mito, mitochondrial
fragmentation, and the Warburg
phenomenon. Expression of the MCU
subunit is post-transcriptionally down-
regulated by several microRNAs (miRs),
notably hsa-miR-138-5p and hsa-miR-25-
3p (henceforth referred to as miR-138 and
miR-25). These miRs also inhibit cAMP
response element–binding protein 1
(CREB1), which transcriptionally
reinforces the down-regulation of MCU.
In normal PASMCs, inhibition of the
MCUC using ruthenium red or small
interfering RNA targeting MCU (si-MCU)
recapitulates the PAH phenotype.
Conversely, restoring MCU expression in
PAH cells, by transfection with the MCU
plasmid or anti-miRs, corrects calcium
homeostasis, mitochondrial dynamics, and
metabolism. In vivo anti–miR-25 and
anti–miR-138 restore MCU expression
and reverse established PAH. These
ﬁndings establish a central and
therapeutically relevant role for the
MCUC in PAH.
The results in the current manuscript
have not been reported previously in any
form.
Methods
Complete methods can be found in the
online supplement.
Cell Culture
PASMC cultures were established from
patients with PAH and control subjects.
The identity of PASMCs was
conﬁrmed morphologically and by
immunohistochemical demonstration of
the presence of smooth muscle a-actin and
the absence of von Willebrand factor.
A primary culture of PASMCs was
established and then the cells were
harvested with trypsin, frozen in freezing
media (10% dimethylsulfoxide, 20% fetal
bovine serum, and 70% M231), and stored
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: Vascular cells in pulmonary
arterial hypertension (PAH) exhibit a
cancer-like phenotype, characterized
by excessive proliferation and
apoptosis resistance. Previous studies
have identiﬁed multiple abnormalities
that may account for this phenotype.
However, there has been insufﬁcient
focus on ﬁnding unifying mechanisms
that explain substantial portions of the
syndrome.
What This Study Adds to the
Field: We report that in PAH,
decreased function of the
mitochondrial calcium uniporter
(MCU) complex, caused primarily by
down-regulation of its MCU subunit,
accounts for much of the cancer-like,
mitochondrial-metabolic phenotype in
PAH. Increased expression of the
microRNAs (miRs) miR-138 and miR-25
down-regulate MCU and cAMP
response element–binding protein 1.
This underlies much of the ionic,
metabolic, and mitochondrial dynamic
ﬁngerprint in PAH. Preclinical studies
suggest that excess proliferation and
apoptosis resistance in PAH can be
reversed by augmenting MCU function.
We also demonstrate the feasibility
of in vivo therapy with nebulized
anti–miR-138 as a novel PAH therapy.
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Figure 1. Reduced expression of the mitochondrial calcium uniporter (MCU) and decreased intramitochondrial calcium in pulmonary artery
smooth muscle cells (PASMCs) in human and experimental pulmonary arterial hypertension (PAH). (A) Representative images and mean values for
intramitochondrial calcium in control subject and patients with PAH measured using a calcium-sensitive fluorescent Fo¨rster resonance energy transfer
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in liquid nitrogen for later use. PASMCs
were used within the ﬁrst six passages in
culture.
Statistics
Values are stated as mean6 SEM. When
applicable, normality was conﬁrmed with
a Kolmogorov-Smirnov test. Intergroup
differences were assessed by Student’s
t tests (unpaired or paired) or analysis
of variance (simple or repeated-measures),
as appropriate. Post hoc analysis was
performed using Tukey test. A P less than
0.05 was considered statistically
signiﬁcant.
Results
Low Intramitochondrial Calcium
Levels and Reduced MCU Expression
in PAH
Assessment of calcium localization using a
FURA probe (for [Ca21]cyto) and a Fo¨rster
resonance energy transfer probe (for
[Ca21]mito) demonstrated elevated
[Ca21]cyto and depressed [Ca
21]mito in
human PAH PASMCs versus control
subjects (Figures 1A and 1B). The
cyclopiazonic acid-releasable sarcoplasmic
reticulum calcium pool was also reduced
in PAH (Figure 1B). To determine which
MCUC subunits mediate this shift in
calcium compartmentalization, an mRNA
expression proﬁle was conducted. This
screen revealed an isolated reduction of
MCU mRNA in human PAH PASMCs
(Figure 1C). Down-regulation of MCU
protein was conﬁrmed in human PASMCs
(Figures 1D and 1E) and the lungs of
patients with PAH (Figure 1F; see Figures
E1A and E1B in the online supplement).
Super-resolution confocal microscopy
showed mitochondrial fragmentation in
PAH PASMCs; moreover, the expression
of MCU was decreased and its normally
well-ordered distribution disrupted
(Figure 1E). Similar down-regulation of
MCU was evident in lungs of rats with
monocrotaline-induced PAH (MCT-
PAH) (Figure 1G; see Figure E2) and
primary cultures of PASMCs derived from
resistance level arteries of rats with MCT-
PAH or exposure to SU5416 plus chronic
hypoxia (see Figure E1C). Of note, cAMP
response element–binding protein 1, a
known regulator of MCU, was also
decreased in the lungs of MCT-challenged
rats (Figure 1G). Although mRNA levels
of other MCUC subunits were unaltered
(Figure 1C), a screen of these proteins by
Western blotting revealed a signiﬁcant
increase in MICU1 in human PAH
PASMCs, and a reduction in MCUb
(Figure 1H; see Figure E3).
Decreasing MCU Expression
Increases [Ca21]cyto and Decreases
[Ca21]mito
Reduction of MCU with small interfering
RNA (siRNA) (see Figures E4A and E4B)
raised [Ca21]cyto (Figure 2A) and
lowered [Ca21]mito (Figure 2B), mimicking
the PAH calcium phenotype (Figure 2C).
[Ca21]cyto was higher in PAH versus
control PASMCs and was reduced
in response to the restoration of
intramitochondrial MCU expression
(Figure 2C) by MCU plasmid transfection
(see Figures E4D, E5, and E6).
Treatment of PASMCs with the
mitochondrial ionophore carbonyl cyanide-
4-(triﬂuoromethoxy)phenylhydrazone
(FCCP) was used to establish the size of the
mitochondrial calcium pool. FCCP caused
a small but consistent release of
mitochondrial calcium into the cytosol in
normal PASMCs (Figure 2A) but had no
effect in PAH PASMCs (Figure 2C).
Transfection of PAH PASMCs with MCU
plasmid created a large FCCP-releasable
calcium pool (Figure 2C), indicating that
restoration of MCU expression replenished
the intramitochondrial pool in PAH
PASMCs.
MCUC Inhibition Causes
Mitochondrial Fission
As reported previously (4), the
mitochondrial network is fragmented in
PAH PASMCs (Figures 2D and 2E). To
conﬁrm that this fragmentation reﬂects
decreased mitochondrial connectivity we
measured the mitochondrial networking
factor (MNF), a validated measure of
ﬁssion (see Video 1) (4, 5). In normal
human PASMCs, siRNA knockdown of
MCU (Figure 2D) or inhibition of MCUC
function with ruthenium red fragmented
the mitochondrial network and decreased
MNF (Figures 2F and 2G), recapitulating
the PAH network morphology. Ruthenium
red induced mitochondrial fragmentation
within 5 minutes (see Video 2). In PAH
PASMCs, the MNF is signiﬁcantly reduced
versus control (Figures 2E–2G). MCU
plasmid transfection of these cells restored
mitochondrial network morphology and
increased MNF.
Inhibition of MCU Mediates the
Warburg Effect in PAH PASMCs
We used micropolarimetry to measure
mitochondrial respiration in cultured
PASMCs (8). When compared with
PAH PASMCs, control PASMCs had a
Figure 1. (Continued). (FRET) probe (a cyan fluorescent protein–calmodulin–yellow fluorescent protein construct) by confocal microscopy (n = 10; **P, 0.01).
The FRET ratio (528/485 nm) depends on the probe’s calmodulin conformation, which is determined by the amount of bound calcium and shown with white
reflecting higher intramitochondrial calcium concentration than red, as described (56). Ratio bar is from 0 to 2.5, scale bar = 5 mm. (B) Cytosolic
calcium, measured using FURA-2, is increased in PAH PASMCs (n = 25; **P, 0.01). The amount of calcium within the sarcoplasmic reticulum (the
pool released by cyclopiazonic acid [CPA]) is reduced in PAH versus control PASMCs (n = 25; **P, 0.01). (C) Quantitative reverse-transcription polymerase
chain reaction measurement of mRNA expression for each of the MCU complex’s components. Only the expression of MCU mRNA is altered in human PAH
PASMCs (n = 6–7; **P, 0.01). (D) Representative immunoblots and densitometric quantification demonstrating decreased MCU protein expression in human
PAH versus control PASMCs (n = 4–7; **P, 0.01). (E) Confocal (left) and stimulated emission depletion (STED) super-resolution (right) images of the mito-
chondrial network of control (top) and PAH (bottom) human PASMCs. In normal patients, STED images reveal that MCU (green) is localized in uniform discrete
bands spanning the inner mitochondrial membrane into the matrix, where NADH dehydrogenase (complex I, red) is located. Scale bar=2 mm for confocal images
and 0.5 mm for STED images. (F) Representative immunohistochemistry of human control versus PAH lungs (of n = 10 per group) demonstrating
increased expression of MCU protein (brown) in the media and endothelium of pulmonary arteries (representative of .10 patients/group; see additional images
in Figures E1A and E1B). The increased medial thickness (arrows) is visible in the small pulmonary arteries of patients with PAH. Scale bar = 100 mm.
Representative immunoblots and densitometric quantification showing (G) decreased expression of MCU and its transcriptional regular cAMP response
element–binding protein 1 (CREB1) in lungs from rats with monocrotaline (MCT)-PAH versus control rats (n = 5/group; **P, 0.01) and (H) increased expression of
mitochondrial calcium uptake protein 1 (MICU1), a negative regulator of MCU, in human PAH PASMCs (n = 5–7; *P, 0.05). EMRE= essential MCU regulator.
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Figure 2. Decreased mitochondrial calcium uniporter (MCU) expression in pulmonary arterial hypertension (PAH) causes a reciprocal increase in
cytosolic calcium concentration and mitochondrial fission. Cytosolic calcium was measured in human pulmonary artery smooth muscle cells (PASMCs)
using fluo-3 and FURA Red (3 mM for 30 min) and expressed as the ratio of 530/640 nm emission measured at 488 nm. (A) Representative and mean
data showing cytosolic calcium concentrations are elevated in normal PASMCs when MCU expression is reduced by exposure to small interfering RNA
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greater oxygen consumption rate (OCR),
and a lower extracellular acidiﬁcation
rate (ECAR, a measure of glycolysis)
(Figure 3A). The glycolysis stress test
(Figure 3B) demonstrated that both
control and PAH PASMCs exhibit similar
responses to glucose stimulation and
inhibition. Control PASMCs also exhibited
a higher ratio of OCR to ECAR
(Figure 3C). In addition, the respiratory
reserve capacity (the increase in OCR
elicited by FCCP) was signiﬁcantly
reduced in PAH PASMCs (Figure 3A).
To determine whether changes in MCU
expression were sufﬁcient to cause these
metabolic changes, we administered
si-MCU to normal PASMCs. si-MCU
reduced the OCR, increased ECAR,
did not change response to glucose
stimulation/inhibition, and signiﬁcantly
decreased the OCR/ECAR ratio,
recapitulating the Warburg effect seen
in PAH PASMCs (Figures 3D–3F).
Conversely, transfection of PAH PASMCs
with the MCU plasmid reversed the PAH
phenotype, reducing uncoupled glycolysis
and increasing the OCR/ECAR ratio
(Figures 3G–3I).
The basis for reduced OCR in PAH
PASMCs is PDH inhibition (Figure 3J).
Moreover, molecular or chemical
inhibition of MCU inhibited PDH activity
in normal PASMCs. This inhibition was
exacerbated in PAH PASMCs. si-MCU
also increased extracellular lactate
production in normal PASMCs
(Figure 3K). Conversely, MCU
overexpression reduces the elevated lactate
production seen in PAH PASMCs. Thus,
changes in MCU subunit expression are
Figure 2. (Continued). targeting MCU (si-MCU) (10 nM for 72 h), partially recapitulating the PAH phenotype (n = 3 individual cell lines per group, with a total of
6–17 cell images per line; *P,0.05, **P,0.01). (B) si-MCU reduces intramitochondrial calcium, demonstrating the role MCU expression plays in establishing
a reciprocal relationship between mitochondrial and cytosolic calcium concentration (n = 3 control human PASMC lines, six discrete cell measurements per line;
*P, 0.05). (C) Cytosolic calcium is higher in PAH versus control PASMCs. Overexpressing MCU by plasmid transfection (1 ng DNA/2 ml for 72 h) lowered
the baseline cytosolic calcium level in PAH PASMCs to near normal control levels (A). In addition, MCU transfection greatly augmented the intramitochondrial
calcium pool (which is reflected by the significantly greater increase in cytosolic calcium), which occurs in response to the mitochondrial uncoupling agent, carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (1 mM) (n = 3 individual cell lines per group, with a total of 6–17 cell images per line; *P, 0.05, **P, 0.01).
(D–G) PASMCs were transfected with photoactivatable, mitochondrial-targeted green fluorescent protein (Mito-PA-GFP) and then loaded with a potentiometric
dye, tetramethylrhodamine (10 nM at 378C for 30 min). Mitochondrial networking was evaluated with photoactivating Mito-PA-GFP as described in the METHODS
section in the online supplement. Mitochondrial networking factor (MNF), a metric that is proportionate to the degree of fusion, is calculated as the number of green
pixels outside the white photoactivation boxes measured in the first image after photoactivation (5 s) divided by the number of green pixels within the activation area,
as previously described (4, 5). Scale bar = 5 mm. Representative images (D and E) and mean6 SEM data (F) show a fused mitochondrial network (high
MNF) in normal human PASMCs versus a fragmented network in identically imaged PAH PASMCs (low MNF). Inhibiting MCU expression in normal PASMCs
(using si-MCU) recapitulates the PAH phenotype. Conversely, MCU overexpression in PAH PASMCs (using MCU plasmid transfection) restores the network fusion
(n = 3 individuals per group, with experiments on each individual cell line repeated five to seven times; *P, 0.05; **P, 0.01). (G) The MCUC inhibitor ruthenium
red (RuR; 10 mM for 48 h) mimics the effects of si-MCU, leading to fragmentation (reduced MNF). RuR had no additional effects on the already fragmented
mitochondrial network of PAH PASMCs (n = 3 individuals per group, with experiments on each individual cell line repeated three to five times; **P, 0.01).
[Ca21]cyto = cytosolic calcium concentration; [Ca
21]mito = intramitochondrial calcium concentration; Con = control; si-control = scrambled siRNA control.
Video 1. Mitochondrial networking is measured using a mitochondria-targeted, photoactivatable green
fluorescent protein (mito-PA-GFP). Mitochondrial networking was evaluated by transfecting pulmonary
artery smooth muscle cells with a Mito-PA-GFP plasmid (FuGENE HD Transfection Reagent, 1 ng/2 ml,
72 h). Cells were also incubated with tetramethylrhodamine (10 nM, 378C, 30 min incubation), a
potentiometric dye, which is taken up by mitochondria in proportion to the negativity of their membrane
potential (red). PA-GFP was photoactivated in a defined area (rectangular boxes). We then calculated
the mitochondrial networking factor, as previously described. In brief, the number of green pixels outside
the activation box was measured at the first image (5 s) after photoactivation and divided by the number
of green pixels (activated PA-GFP) inside the boxed activation area. Scale bar = 1 mm. The movie
duration is 2 minutes. The mitochondrial network was imaged with a Leica STED super-resolution
confocal microscope (Leica, Wetzlar, Germany) at 363 magnification and 34 digital zoom.
Video 2. The mitochondrial calcium uniporter complex inhibitor ruthenium red causes mitochondrial
fission. The mitochondrial network was imaged with a Leica STED super-resolution confocal
microscope (Leica, Wetzlar, Germany) at 3100 magnification and 34 digital zoom. Cells were loaded
with MitoTracker Green (100 nM for 20 min at 378C; ThermoFisher Scientific, Waltham, MA) and
imaged both (A) before and (B) after ruthenium red at excitation/emission wavelengths of 488 and
530 nm, respectively. The total image size is 38.7 mm2. The duration of both movies is 5 minutes.
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Figure 3. Mitochondrial calcium uniporter (MCU) gene transfer restores pyruvate dehydrogenase (PDH) activity and improves the coupling of glycolysis to
glucose oxidation in pulmonary arterial hypertension (PAH) pulmonary artery smooth muscle cells (PASMCs). (A–I) Oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR) as markers of mitochondrial and glycolytic flux were measured in PASMCs using the Seahorse XFe24 Extracellular
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sufﬁcient to explain many aspects of the
PAH metabolic phenotype.
Manipulation of MCUC Inhibition
Modulates PASMC Migration,
Proliferation, and Apoptosis
We assessed whether modulating MCU
expression could alter PASMC function, as
measured by migration and proliferation
(Figure 4). PASMC migration was
stimulated using platelet-derived growth
factor (PDGF), a mitogen that is up-
regulated in PAH, and measured using a
modiﬁed Boyden chamber and the
Xcelligence analyzer (Acea Biosciences Inc.,
San Diego, CA). Inhibiting MCUC using
ruthenium red enhanced migration of
both control and PAH PASMCs (Figures
4A and 4B). Although there was no additive
effect of combining PDGF and ruthenium
red in normal PASMCs, inhibiting the
MCUC further increased the rate of migration
in PAH PASMCs (Figures 4A and 4B).
Proliferation rates were higher in
PAH than control PASMCs (Figure 4C).
Chemical or molecular inhibition of
the MCUC increased proliferation in
normal and PAH PASMCs (Figures 4C
and 4D). Conversely, MCU transfection
reduced cell proliferation in control and
PAH PASMCs (Figure 4E). Knockdown
of MICU1 with siRNA (see Figures
E4C and E4D) also reduced PASMC
proliferation rates in PAH PASMCs but
had no effect on control PASMCs
(Figure 4F), consistent with the
interpretation that some of the enhanced
cell proliferation in PAH reﬂects
inhibition of MCUC by MICU1, MCU’s
negative regulator (Figure 1H). Restoring
MCU expression also increases basal
apoptosis rates in PAH PASMCs
(Figure 4G).
miR-138 and miR-25 Mediate Post-
transcriptional Down-regulation of
MCU
We next assessed the molecular basis for
depressed MCU expression in PAH.
MCU is regulated at the transcriptional
level by CREB1 (28), and at the post-
transcriptional level by one or more miR
(29). In addition to previous reports
demonstrating that miR-25 down-
regulates MCU expression in cancer
cells (29) and cardiomyocytes (30),
in silico analysis using Target Scan 7.0
(http://www.targetscan.org/vert_70/) and
miRDB (http://mirdb.org/miRDB/index.
html) identiﬁed miR-138, miR-124, and
miR-129 as potentially targeting MCU.
Assessment of miR expression by quantitative
reverse-transcription polymerase chain
reaction identiﬁed a signiﬁcant elevation
in miR-138 and a trend toward increased
miR-25 in PAH PASMCs (Figure 5A). No
differences were observed in the expression
of other miRs (data not shown).
In addition, we compared miR
expression in PASMCs from six patients
with PAH and three healthy subjects using
the Affymetrix miRNA 4.0 Microarray
(Affymetrix, Santa Clara, CA). Using a
prespeciﬁed difference threshold of 1.53,
we identiﬁed six up-regulated miRs in PAH
(P, 0.05) (see Table E1). None of these
species have previously been reported to
target MCU and none were identiﬁed by our
in silico analysis as prospective MCU targets.
Therefore, these miR species were not
further pursued in this initial study.
In silico target prediction using
nucleotide BLAST shows that miR-138
has three predicted target sites within the
39-UTR of MCU, one of which has an
Expect value of 0.36, suggesting a very high
likelihood of interaction (see Figures E7A
and E7B). In addition, miR-25 has two
predicted sites of interaction with MCU’s
39-UTR (Expect values 1.3 each) (see Figures
E7A and E7C). Binding of miR-25 and
miR-138 to the 39-UTR of MCU was
directly conﬁrmed in vitro using a luciferase
reporter fused to the 39-UTR of the MCU
gene. Cotransfection of HEK293A cells with
either miR-25 or miR-138 and the reporter
construct resulted in decreased luciferase
production, conﬁrming binding of these
miRs to the 39-UTR of MCU (Figure 5B).
These same miRs also regulate CREB1
expression. miR-138 has a predicted target
site within CREB1’s 39-UTR (Expect value
1.1). Likewise, miR-25 has three predicted
target sites (Expect value 1.1 for each)
(see Figures E7D–E7F). To more directly
determine the relationship between miR-138
and CREB1 we administered anti–miR-138
and anti–miR-25 to PAH PASMCs and
observed that both increased expression of
MCU and CREB1 (Figures 5C and 5D),
although the therapeutic efﬁcacy varied
among individual patients (see Figures E8A
and E8B). Thus, the miRs are regulating
both MCU and CREB1. Importantly, these
beneﬁcial changes were observed in the
absence of any signiﬁcant effect of anti-miRs
on miR-25 or miR-138 expression levels
(see Figures E8C and E8D). This ﬁnding is
in keeping with the fact that anti-miRs do
not function by reducing miR levels but
instead act by preventing the binding of
these miRs to the 39-UTR of target genes.
Because CREB1 is potentially both a
target for and a regulator of miRs (31) we
inhibited CREB1 in normal PASMCs using a
validated si-CREB1 (Figure 5E). The absence
of elevated miR expression despite successful
down-regulation of CREB1 indicates that
miRs are the upstream regulators of the
MCU pathway (Figures 5E and 5F).
Figure 3. (Continued). Flux Analyzer (Seahorse XFe24, Agilent Technologies Canada Inc., Mississauga, ON, Canada), as previously described (8). All
measurements were made on n = 25,000–50,000 cells/well and five wells per cell line (sample). Each experimental group consisted of two to three patient cell
lines (samples). All data were normalized to total protein per well before analysis. (A) OCR (left) is higher and ECAR (right) is lower in naive normal PASMCs
compared with PAH PASMCs. (B) Glycolytic activity is higher in naive PAH PASMCs compared with normal. (C) Naive normal PASMCs have a higher OCR/ECAR
ratio than PAH PASMCs (****P,0.0001). (D) Silencing MCU using small interfering RNA targeting MCU (si-MCU) reduced OCR (left) and increased ECAR (right)
in normal PASMCs. (E) SilencingMCU increased glycolytic activity in normal PASMCs. (F) si-MCU decreases the OCR/ECAR ratio in normal PASMCs (****P,0.0001).
(G) OCR is markedly reduced in PAH PASMCs with and without MCU overexpression (MCU ox) (vs. control PASMCs; note smaller scale compared with A and D).
Overexpression of MCU (via transfection of MCU plasmid) has little effect on OCR (left) but disproportionately lowers ECAR (right). (H) Glycolytic activity
is decreased in PAH PASMCs with MCU overexpression compared with control PAH. (I) MCU overexpression increases the OCR/ECAR ratio in PAH PASMCs
(****P,0.0001). (J) Representative images andmean data (n= 4/group; *P,0.05) showing that PDH activity is greater in control PASMCs than in PAH PASMCs and
that in both cell types PDH activity is inhibited by the MCU complex inhibitor ruthenium red (RuR; 10 mM) or Si-MCU. PDH activity was measured in
homogenized PASMCs using a PDH activity dipstick in which the intensity of the nitroblue tetrazolium band (arrows) is proportionate to enzyme activity (ab109882;
MitoSciences-Abcam, Eugene, OR). (K) Lactate production is increased in normal PASMCs by inhibiting MCU expression (using si-MCU) and is reduced in PAH
PASMCs by overexpressing MCU (by plasmid transfection) (n = 4; *P, 0.05). Data in panels A, B, C, D, and H are mean6 SEM. 2-DG=2-deoxyglucose; Anti
A/Rote=antimycin A and rotenone; FCCP=carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; NC=negative control small interfering RNA.
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However, both miRs target CREB1’s 39-UTR
and the resulting CREB1 down-regulation
would be expected to reinforce MCU down-
regulation. Supporting this interpretation, si-
CREB1 reduces MCU expression in normal
human PASMCs (Figure 5F). This is highly
relevant because CREB1 expression is
reduced in human PAH PASMCs (Figures
5G and 5H) and in lung homogenates of rats
with MCT-PAH (Figure 1G). Moreover,
serine-133 phospho-CREB1, the transcription
factor’s activated form (32), is down-regulated
in PAH (Figure 5G). To assess CREB1
activity we measured the incidence and
intensity of nuclear CREB1 expression using
immunoﬂuorescence. CREB1 activity was
reduced in PAH and fewer PAH PASMCs
had detectable nuclear CREB1 (Figure 5H).
Inhibition of miR-138 and miR-25
Reverses the MCT Rat Model of PAH
To assess the biologic impact of miR-25
and miR-138 up-regulation on the
pathogenesis of PAH, rats with mild
established MCT-induced PAH were
nebulized with the anti-miRs (anti–miR-
138, anti–miR-25, or anti–miR-control)
(Figure 6A). Nebulization of anti–miR-25
or anti–miR-138 signiﬁcantly attenuated
disease progression in the MCT model
(Figures 6B–6D). The improvements were
comprehensive and included reduction in
total pulmonary vascular resistance, the
result of a large reduction in mean
pulmonary artery pressure, and marked
increase in cardiac output and RV
function, accompanied by a reduction in
RV end diastolic pressure and right
ventricular hypertrophy. In addition,
functional capacity improved dramatically
with both anti-miRs (Figure 6B; see Figure
E9). Consistent with the ﬁnding that miR-
138 was the most elevated MCU-targeting
species in PAH PASMCs, inhaled
anti–miR-138 was more effective in
increasing stroke volume than anti–miR-
25 (Figure 6B; see Figure E9). Both
anti–miR-138 and anti–miR-25 lowered
plasma levels of brain natriuretic peptide
to control levels, consistent with a
reduction in RV pressure/volume overload
(see Figure E10). These hemodynamic
beneﬁts were accompanied by regression
of vascular obstruction, as quantiﬁed by a
decrease in medial thickness in small
pulmonary arteries (Figures 6C and 6D),
and a restoration of MCU expression in
the pulmonary arteries of MCT-challenged
rats (Figure 6E). Dual staining of lung
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Figure 4. Pulmonary artery smooth muscle cell (PASMC) migration, proliferation, and apoptosis are
regulated by the mitochondrial calcium uniporter (MCU). (A and B) PASMC migration (basal or
stimulated by platelet-derived growth factor [PDGF]) was measured using the iCELLigence system, an
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sections for MCU and either smooth
muscle cell a-actin (Figure 6E) or
endothelial CD31 (see Figure E11) suggest
that the beneﬁcial effects of anti-miR
treatment were likely caused by a restoration
of MCU in the vascular smooth muscle
cell layer. However, we cannot exclude an
additional direct beneﬁt on the pulmonary
endothelium or the RV, because MCU
down-regulation also occurred in the RV of
rats with MCT-PAH (see Figure E12).
Discussion
Impaired MCUC function is central to the
mechanism of human and experimental
PAH. MCUC dysfunction is caused by
decreased expression of MCU subunit,
exacerbated by up-regulation of MICU1, an
inhibitory complex subunit. Decreased
MCU expression is initiated by an increase
in several miRs, notably miR-138 and
miR-25. miR-induced MCU down-
regulation is reinforced by miR-induced
down-regulation of MCU’s transcriptional
regulator, CREB1. This miR-CREB1-
MCUC pathway is schematically
illustrated in Figure 6E.
In normal vascular myocytes the
mitochondrion’s buffering capacity
attenuates increases in [Ca21]cyto caused by
increased inﬂux of extracellular calcium or
calcium released from the sarcoplasmic
reticulum. By attenuating the magnitude
and duration of elevations in [Ca21]cyto,
mitochondria limit vasoconstriction,
cell migration, proliferation, and
mitochondrial ﬁssion. Additionally,
mitochondrial calcium inﬂux through
the MCU activates calcium-sensitive
dehydrogenases, such as PDH. The
reduction in [Ca21]mito, which has
previously been noted in PAH (Figure 1)
(33), inhibits calcium-sensitive
dehydrogenases in the mitochondrial
matrix (Figure 3J). When PDH activity is
reduced oxidative metabolism declines,
forcing a bioenergetic reliance on aerobic
glycolysis, a metabolic switch referred to as
the Warburg phenomenon (Figure 3) (10).
Several lines of evidence indicate that
impaired MCUC function is critical to
disease pathogenesis. For example, in
normal human PASMCs, inhibiting the
MCUC replicates the PAH phenotype,
whether achieved using ruthenium red or
si-MCU. In these normal PASMCs,
MCU inhibition is sufﬁcient to increase
mitochondrial ﬁssion and reduce glucose
oxidation, increasing cell proliferation and
migration (Figure 4). Conversely, in PAH
PASMCs, restoring MCU expression by
MCU gene transfer lowers [Ca21]cyto and
repletes [Ca21]mito (Figure 2). Moreover,
MCU gene transfer in PAH PASMCs reduces
the rate of cell proliferation and migration
while increasing both oxidative glucose
metabolism and apoptosis (Figures 3 and 4).
Although there are many causes of
abnormal metabolism in PAH, including
PDH kinases–mediated PDH inhibition (3),
it is clear that MCU function, through its
ability to regulate [Ca21]mito, has a major
effect on PDH activity. In normal PASMCs,
si-MCU inhibits PDH and recapitulates the
Warburg phenomenon (Figure 3). These
metabolic effects of si-MCU are mimicked
by ruthenium red (Figure 3). Conversely,
augmenting MCU expression in PAH
PASMCs reverses the Warburg phenotype,
restoring oxidative glucose metabolism,
suggesting a potential therapeutic strategy
(Figure 3).
PAH PASMCs have a second
prominent mitochondrial abnormality,
namely mitochondrial fragmentation
caused by increased ﬁssion (4) and
impaired fusion (11) (Figure 2) (34). In
PAH and cancer, increased mitotic ﬁssion
is mediated in part by phosphorylation of
Drp1 at serine-616. Increased ﬁssion
permits rapid cell division, and is
coordinated with mitosis via shared
dependence on cyclin B-CDK1 (34).
Numerous additional Drp1-activating
stimuli exist in the PAH milieu, including
increased [Ca21]cyto (Figure 2), which
activates calmodulin kinase, which in turn
phosphorylates and activates Drp1 (35).
We demonstrate that in normal PASMCs,
reducing MCU expression or inhibiting
MCUC function increases mitochondrial
ﬁssion (Figure 2). Conversely, restoring
MCU expression in PAH PASMCs is
sufﬁcient to fuse the PAH mitochondrial
network (Figures 2D–2G).
miRNA dysregulation in the RV,
skeletal muscle, and pulmonary vasculature
contributes to the progression of PAH
(36–39). The following miRs are up-
regulated in PAH PASMCs and endothelial
cells: miR-130/301, miR-145, miR-21,
miR-190, miR-29b, miR-17/92, miR-125,
and miR-210 (36, 40). These miRs regulate
the following pathways that are relevant
to PAH pathophysiology: PPARg (41),
BMPR-II (42, 43), KLF4–5 (44), voltage-
gated potassium channels (45), and STAT3
(46). However, this is the ﬁrst report of the
role of miR-138 in either MCU regulation
or the development of PAH (Figure 5A).
Although miR-138 up-regulation was
previously noted in human PAH, its
functional importance was not explored
(47). Hypoxia-induced increases in
miR-138 promote apoptosis resistance
and worsen hypoxic pulmonary
hypertension by targeting the proapoptotic
serine/threonine kinase, MST1, thereby
preventing caspase activation and
disrupting Bcl-2 signaling (40). Consistent
with this report, we observed that MCU
down-regulation promoted apoptosis
resistance, which was reversed by restoring
MCU expression (Figure 4G). Our ﬁndings
are also consistent with the apoptosis
resistance that occurs in cancer due to
MCU down-regulation (29, 48).
miR-138 also causes endothelial
dysfunction and impairs tube formation by
diminishing vascular endothelial growth
factor–induced nitric oxide production
through a mechanism involving S100A1 (49).
Figure 4. (Continued). impedance-based system of measuring cell number and cell movement (ACEA Biosciences, San Diego, CA) wherein higher slope
indicates faster migration. Ruthenium red (RuR; 10 mM for 6 h) increased PASMCmigration in control (A) and pulmonary arterial hypertension (PAH) (B) PASMCs.
The increase was additive to that achieved with PDGF in PAH PASMCs (*P , 0.05; n = 3/group). (C and D) Rates of PASMC proliferation are faster in PAH
versus control PASMCs. RuR (10 mM for 37–41 h) and small interfering RNA targeting MCU (si-MCU) increase rates of cell proliferation in both control and PAH
PASMCs (**P,0.01; n =5/group). Proliferation was measured using a Click-iTEdU kit (Invitrogen, Waltham, MA) according to the manufacturer’s instructions. (E)
Transfection with the MCU plasmid reduces rates of cell proliferation in both control and PAH PASMCs. Values are mean6 SEM; **P, 0.01; n = 5/group. (F)
Inhibition of the negative regulator of the mitochondrial calcium uniporter complex, mitochondrial calcium uptake protein 1 (MICU1), using si-MICU1, reduces
cell proliferation in PAH PASMCs (**P, 0.01; n = 4/group). (G) Transfection with the MCU plasmid increases baseline apoptosis in PAH PASMCs cultured
in serum (*P , 0.05; n = 4/group).
ORIGINAL ARTICLE
524 American Journal of Respiratory and Critical Care Medicine Volume 195 Number 4 | February 15 2017
 
H0
20
40
60
CR
EB
 (+
) n
uc
lei
 (%
)
*
Control PAH
0
10
20
30
*
CR
EB
 In
te
ns
ity
(A
FU
)
Control PAH
CREB IF
Negative
controlPAHControl
CREB + DAPI
G
CREB mRNA
*
Control PAH
R
el
at
iv
e 
to
 β
-
a
ct
in
0.0
0.5
1.0
1.5
CREB
β-actin
Control
Ser-133p-CREB
p-ATF-1
PAH
0.0
0.5
1.0
1.5
Control PAH
**
p-CREB proteinCREB protein
Control
**
PAH
R
el
at
iv
e 
to
 β
-
a
ct
in
0.0
0.5
1.0
C
PAH PASMC
MCU
An
ti-m
iR-
co
ntr
ol
An
ti-m
iR-
25
An
ti-m
iR-
13
8
An
ti-m
iR-
co
ntr
ol
An
ti-m
iR-
25
An
ti-m
iR-
13
8
β-actin β-actin
*
*
0
1
2
3
4
An
ti-m
iR-
co
ntr
ol
An
ti-m
iR-
25
An
ti-m
iR-
13
8
M
CU
 E
xp
re
ss
io
n
R
el
at
iv
e 
to
 C
on
tro
l 
D
PAH PAMSC
CREB1
*
*
0.0
0.5
1.0
1.5
2.0
An
ti-m
iR-
co
ntr
ol
An
ti-m
iR-
25
An
ti-m
iR-
13
8
CR
EB
1 
Ex
pr
es
sio
n
R
el
at
iv
e 
to
 C
on
tro
l
miR-138
0
1
2
3
4
5
m
iR
-1
38
 re
la
tiv
e 
to
R
UN
48
*
Control PAH
miR-25
Control PAH
0
1
2
3
m
iR
-2
5 
re
la
tiv
e 
to
R
UN
48
A B
0
1
2
3
4
5
miR-control miR-138
R
el
at
iv
e 
lu
ci
fe
ra
se
a
ct
iv
ity *
0
2
4
6
8
miR-control miR-25
*
R
el
at
iv
e 
lu
ci
fe
ra
se
a
ct
iv
ity
MCU 3’-UTR Binding
F
CREB
β-actin
MCU
si-Control si-CREB
CREB protein
**
si-
CR
EB
si-
Co
ntr
ol
R
el
at
iv
e 
to
 β
-
a
ct
in
0.0
0.5
1.0
*
MCU protein
si-
CR
EB
si-
Co
ntr
ol
R
el
at
iv
e 
to
 β
-
a
ct
in
0.0
0.5
1.0
E
m
iR
-2
5 
Ex
pr
es
sio
n
R
el
at
iv
e 
to
 C
on
tro
l 
0.0
0.5
1.0
1.5
si-
Co
ntr
ol
si-
CR
EB
CR
EB
1 
Ex
pr
es
sio
n
R
el
at
iv
e 
to
 C
on
tro
l
0.0
0.5
1.0
1.5
si-
Co
ntr
ol
si-
CR
EB
***
m
iR
-1
38
 E
xp
re
ss
io
n
R
el
at
iv
e 
to
 C
on
tro
l
*
0.0
0.5
1.0
1.5
si-
Co
ntr
ol
si-
CR
EB
Figure 5. Down-regulation of mitochondrial calcium uniporter (MCU) results from increased expression of microRNA (miR)-138 but is reinforced by miR-25 and
reduced expression of cAMP response element–binding protein 1 (CREB1). The nomenclature of miRs is in evolution, and because the sequence of rat and human
miRs is the same, we use the more generic names, miR-138 and miR-25. However, all anti-miRs were constructed against the human miR sequences for
hsa-miR-138-5p and hsa-miR-25-3p. (A) Expression of miR-138 is increased in pulmonary arterial hypertension (PAH) pulmonary artery smooth muscle cells
(PASMCs) (*P,0.01; n =9–12/group). Note the trend for increased expression of miR-25 (P=NS). (B) HEK293A cells were transfected with a luciferase reporter
bearing the 39-UTR of the MCU gene, as well as a miR control, (A) miR-25 or (B) miR-138. Both miR-25 and miR-138 were found to repress the activity of luciferase
reporter, indicating their binding to their target sites in the MCU 39-UTR (*P,0.05; n =6). (C and D) Anti–miR-138 and anti–miR-25 restore expression of (C)
MCU and (D) CREB1 mRNA (top) and protein (bottom) (*P,0.01; n=3/group). (E) CREB small interfering RNA (si-CREB) does not significantly increase expression
of miR-25 or miR-138 (*P,0.05; ***P,0.001; n=3/group). (F) si-CREB1 transfection reduces the expression of CREB1 in normal PASMCs (immunoblot and
aggregate data) (*P,0.05; **P,0.01; n =4/group). This leads to a reduction in the expression of MCU protein, thereby confirming the relevance of the observed
down-regulation of CREB1 in PAH to the associated reduction in MCU expression in PAH (Figure 6B). (G) Quantitative reverse-transcription polymerase chain reaction
(top) and immunoblot and aggregate data showing that CREB1 and phospho-CREB1 (serine-133; Ser-133p-CREB) expression are decreased in PAH versus
control PASMCs (*P, 0.05; **P,0.01; n=4–6/group). (H) Representative images and mean data showing that expression of activated CREB1, defined as CREB IF
(green) in the PASMC nucleus, is increased in PAH (middle column). Scale bars=10 mm (top) and 50 mm (bottom). CREB1 intensity is expressed in arbitrary
fluorescent units (AFU). In addition, a higher percentage of PAH PASMCs versus control PASMCs have detectable CREB1 immunofluorescence in the nucleus
(colocalized with 49,6-diamidino-2-phenylindole [DAPI]) (*P , 0.05; n =3 lines per group; discrete three to four measurements per line). The negative control had no
primary antibody. p-ATF-1=activating transcription factor-1; si-control = scrambled siRNA control; UTR=untranslated region.
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Finally, miR-138 is an important regulator
of the DNA damage response, which has
been implicated in the pathophysiology of
PAH (50). Although the increase in miR-25
expression in PAH did not achieve
statistical signiﬁcance, the therapeutic
response to anti–miR-25 conﬁrms that it
contributes to decreased MCU expression
and to the pathogenesis of PAH (Figures 5B
and 6B). MCU regulation by miR-25 has
previously been described in cancer cells
(29), although the effects of manipulating
miR-25 on cell metabolism and
proliferation rates had not previously been
assessed.
In addition to post-transcriptional
down-regulation of MCU, miR-25 and miR-
138 reduce CREB1 activation in PAH
(Figures 5E–5G). Prior studies reported a
PDGF-initiated, PI3K/Akt-mediated
CREB1 down-regulation in PASMCs from
animals with hypoxic pulmonary
hypertension, noting it increased PASMC
migration and proliferation (51). We found
that si-CREB1 reduces MCU expression in
normal PASMCs (Figure 5E). However,
using in silico technique we identiﬁed
several sites in CREB1’s 39-UTR that are
predicted to bind miR-138 and miR-25.
Because CREB1 expression increases in
response to both antagomirs this suggests
the miRs are upstream of CREB1. Thus, in
PAH MCU down-regulation occurs directly
as a result of inhibition of MCU expression
by the miRs, and indirectly by miR-induced
CREB1 down-regulation.
The therapeutic potential of restoring
MCU expression was tested directly
(by MCU transfection in PASMCs) (Figures
2–4) and indirectly (miR-25 and miR-138
anti-miRs) (Figures 5B and 5C). Restoring
MCU expression in PASMCs reduces
mitochondrial ﬁssion (Figure 2), restores
glucose oxidation, reverses the Warburg
effect (Figure 3), and decreases the
pathologic rates of cell motility and
migration (52) and proliferation (4, 11)
that characterize PAH (Figure 4). Although
we show that the anti-miRs restore MCU
expression in human PAH PASMCs
(Figure 5C), the more rigorous test of
therapeutic relevance was conducted
in vivo. We demonstrated that nebulized
antagomirs targeting miR-25 and miR-138
completely regressed MCT-induced PAH
(Figure 6B; see Figure E9).
In our study, loss of MCU function is
pathologic and therapeutic beneﬁt is
gained by restoring MCU expression;
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Figure 6. Anti-microRNA (miR) therapy regresses pulmonary arterial hypertension (PAH) in vivo. (A)
Protocol for the administration of the anti-miRs in rats with established PAH. Ten days after injection
of monocrotaline (MCT; 60 mg/kg subcutaneous; n = 10 rats/group) rats were anesthetized and
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however, disease context does matter.
For example, mice with a homozygous
deletion of MCU have normal cardiac
function at rest and in response to
increased afterload or isoproterenol (53).
In conditions where intramitochondrial
calcium is severely elevated, such as heart
failure (54), subarachnoid hemorrhage
(55), and ischemia reperfusion injury
(30), inhibition of MCU may prevent
mitochondrial further calcium overload
and preserve organ function. For
example, in cardiomyocytes, oxidative
stress increases miR-25, which binds
the 39-UTR of MCU, down-regulating
its expression and exerting a protective
effect by decreasing excessive
H2O2-induced increases in [Ca
21]mito
(30). These examples occur in a very
different context than PAH, where
MCU is down-regulated and
intramitochondrial calcium
concentrations are pathologically
reduced.
The miR-MCU pathway is likely
downstream from triggers of PAH
that may be genetic (mutations of bone
morphogenetic protein receptor 2),
epigenetic (gene silencing by CpG
methylation), environmental (related
to toxins and drugs that modify the
serotonin signaling pathway, such as
dexfenﬂuramine), or inﬂammatory.
Nonetheless, impaired MCUC activity,
due largely to reduced MCU expression,
constitutes a unifying mechanism
for the overload in [Ca21]cyto and
reduction in [Ca21]mito that alter
mitochondrial dynamics and metabolism,
respectively, and which thereby drive
PAH’s cancer-like phenotype.
Restoration of MCUC function has a
large therapeutic beneﬁt, whether
achieved by plasmid transfection of
the MCU gene in PASMCs or by
nebulized anti-miRs in vivo (schematic,
Figure 6E). This suggests MCU and
[Ca21]mito are important new targets for
therapy of proliferative, apoptosis-
resistant diseases, such as PAH and
cancer. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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